The UAB Division of Endocrinology, Diabetes, and Metabolism, alongside the Division of Endocrine Surgery, is pleased to host the 2025 UAB Endocrinology Update Conference on Saturday, August 23 beginning at 8 a.m. at the Hilton Birmingham at UAB. 

 As a lab manager, Khadija Seck oversees daily lab operations and helps coordinate experiments in the Habegger Lab.

Haifa Alsharif, Ph.D., a postdoctoral scholar in the UAB Comprehensive Diabetes Center (UCDC), won first place for her poster presentation at the UAB Department of Medicine’s 2025 Trainee Research Symposium (TRS).

A new study by Rita Basu, M.D., and collaborators, finds that restoring hepatic glycogen improves nocturnal glucose regulation in humans with Type 2 diabetes.

UAB Comprehensive Diabetes Center (UCDC) Director Anath Shalev, M.D., was invited to present at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), held in Amsterdam, March 19-22.

UAB is ranked No. 164 based on exceptional academic research portfolio and its overall global and regional reputation.

In Fall 2024, UAB Heersink School of Medicine announced the winners of the 2024 Dale J. Benos Medical Student Research Day (MSRD).

Blazer Bridge Fund provides financial support to innovative ideas and inventions by the UAB community, encouraging advanced discovery. 

A cluster analysis in the Deep South showed that racial background significantly influences diabetes subtype distribution.

The novel drug TIX100 functions differently from any approved diabetes drug to promote proper islet cell function.

For 11 consecutive years, U.S. News has named UAB Hospital the best hospital in Alabama, with several specialties and procedures ranked among the best.

This advance should facilitate atherosclerosis drug discovery and development.

Department of Medicine Facilities Coordinator Corey Cates, M.S., was six years old when he was diagnosed with Type 1 diabetes. For doctors to uncover Cates’ diagnosis, it took a two-and-a-half-hour drive as well as a one-week stay at the Children's Medical Center in Dallas, TX in 1996.

Continuous glucose monitors and insulin pumps can help patients “live a quality life without burning out on managing diabetes,” said Ananda Basu, M.D., director of the Diabetes Technology Program at UAB.

UAB diabetes expert serves up tailgating hacks to make football season fun and diabetes-friendly.

These results add an additional, mechanistic aspect to further explain how the decades-old blood pressure medication verapamil can preserve beta cell function in Type 1 diabetes patients by affecting the hormone insulin-like growth factor 1.

The UAB Division of Endocrinology, Diabetes, and Metabolism, alongside the Division of Endocrine Surgery, is pleased to offer the 2023 Endocrinology Update Conference on Saturday, August 19 beginning at 8 a.m. at the Hilton Birmingham at UAB.

In the last several years, UAB Medicine and Heersink School of Medicine have worked to bring leadership development to faculty and staff through the UAB Medicine Institute for Leadership and Momentum in Medicine programs.

The University of Alabama at Birmingham Heersink School of Medicine and the UAB Comprehensive Diabetes Center (UCDC) are pleased to welcome Ananda Basu, M.D., and Rita Basu, M.D., as full professors into the Division of Endocrinology, Diabetes, and Metabolism.

In just the five years since UAB completed 10,000 robotic surgeries, surgeons across 15 disciplines have now collectively exceeded 20,000 robotic surgeries, setting a record for the hospital.

Continuous glucose monitors can transform one’s diabetes treatment and care. A UAB diabetes expert explains what patients should know about the devices when evaluating their diabetes care plans.

Continuous glucose monitors are “such a useful and impactful behavior modification tool” that half of his patients with Type 1 and Type 2 diabetes now use these devices, said Fernando Ovalle, M.D., director of UAB’s Multidisciplinary Comprehensive Diabetes Clinic. Learn how data leads to better decisions and better control of diabetes.

Anath Shalev, M.D., did everything she could to change treatment for Type 1 diabetes from her lab, but getting to first-in-human trials meant taking a step she had always resisted. The most surprising thing about launching a startup, though?

UAB’s research and reputation land it among the top institutions in the world.